Elevated complement C3 and increased CD8 and type 1 helper lymphocyte T populations in patients with post-COVID-19 condition.


Journal

Cytokine
ISSN: 1096-0023
Titre abrégé: Cytokine
Pays: England
ID NLM: 9005353

Informations de publication

Date de publication:
09 2023
Historique:
received: 14 03 2023
revised: 28 06 2023
accepted: 05 07 2023
medline: 11 8 2023
pubmed: 16 7 2023
entrez: 15 7 2023
Statut: ppublish

Résumé

Biological markers associated to post-COVID-19 condition (PCC) have not been clearly identified. Eighty-two patients attending our post-COVID-19 outpatient clinic were recruited and classified as fully recovered (40.2%) or presenting with PCC (59.8%). Clinical and radiological data, laboratory markers, cytokines, and lymphocyte populations were analyzed. Median number of days after hospitalization was 78.5 [p25-p75: 60-93] days. PCC was significantly more frequent in women, in patients with a previously critical COVID-19, and in those with two or more comorbidities. No differences were found in lymphocyte counts, ferritin, C-reactive protein, D-dimer or sCD25, IL-1β, IL-1Ra, IL-6, CXCL8, IL-17A, IL-18, IL-22, IFN-γ, TNF-α, and IL-10 cytokines levels. PCC patients showed significantly higher levels of complement factor C3 than fully recovered patients: median C3 128 mg/dL [p25-p75:107-135] vs 111 mg/dL [p25-p75: 100-125] (p =.005), respectively. In the flow cytometry assessment of peripheral blood lymphocyte subpopulations, PCC patients showed significantly increased CD8 populations compared to fully recovered patients: median CD8: 529 [p25-p75: 384-683] vs 370/mm Patients with a post-COVID-19 condition showed significantly increased immunological parameters of inflammation (complement factor C3 and CD8 and Th1 T lymphocyte populations) compared to fully recovered patients. These parameters could be used as biological markers of this condition.

Sections du résumé

BACKGROUND
Biological markers associated to post-COVID-19 condition (PCC) have not been clearly identified.
METHODS
Eighty-two patients attending our post-COVID-19 outpatient clinic were recruited and classified as fully recovered (40.2%) or presenting with PCC (59.8%). Clinical and radiological data, laboratory markers, cytokines, and lymphocyte populations were analyzed.
RESULTS
Median number of days after hospitalization was 78.5 [p25-p75: 60-93] days. PCC was significantly more frequent in women, in patients with a previously critical COVID-19, and in those with two or more comorbidities. No differences were found in lymphocyte counts, ferritin, C-reactive protein, D-dimer or sCD25, IL-1β, IL-1Ra, IL-6, CXCL8, IL-17A, IL-18, IL-22, IFN-γ, TNF-α, and IL-10 cytokines levels. PCC patients showed significantly higher levels of complement factor C3 than fully recovered patients: median C3 128 mg/dL [p25-p75:107-135] vs 111 mg/dL [p25-p75: 100-125] (p =.005), respectively. In the flow cytometry assessment of peripheral blood lymphocyte subpopulations, PCC patients showed significantly increased CD8 populations compared to fully recovered patients: median CD8: 529 [p25-p75: 384-683] vs 370/mm
CONCLUSION
Patients with a post-COVID-19 condition showed significantly increased immunological parameters of inflammation (complement factor C3 and CD8 and Th1 T lymphocyte populations) compared to fully recovered patients. These parameters could be used as biological markers of this condition.

Identifiants

pubmed: 37453328
pii: S1043-4666(23)00173-4
doi: 10.1016/j.cyto.2023.156295
pii:
doi:

Substances chimiques

Complement C3 0
Cytokines 0
Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

156295

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Mercedes Garcia-Gasalla (M)

Department of Internal Medicine, Hospital Universitari Son Espases, Palma, Spain; Balearic Islands Health Research Institute (IdISBa), Palma, Spain; Universitat de les Illes Balears. Palma de Mallorca, Illes Balears, Spain. Electronic address: mercedes.garcia@uib.es.

Maria Berman-Riu (M)

Balearic Islands Health Research Institute (IdISBa), Palma, Spain; Universitat de les Illes Balears. Palma de Mallorca, Illes Balears, Spain.

Adrian Rodriguez (A)

Balearic Islands Health Research Institute (IdISBa), Palma, Spain; Department of Internal Medicine, Hospital Universitari Son Llàtzer, Palma, Spain.

Amanda Iglesias (A)

Balearic Islands Health Research Institute (IdISBa), Palma, Spain; Centro de Investigación Biomedica en Red (CIBER) de Enfermedades Respiratorias, Hospital Universitari Son Espases, Palma, Spain.

Pablo A Fraile-Ribot (PA)

Balearic Islands Health Research Institute (IdISBa), Palma, Spain; Department of Microbiology, Hospital Universitari Son Espases, Palma, Spain.

Nuria Toledo-Pons (N)

Balearic Islands Health Research Institute (IdISBa), Palma, Spain; Department of Pneumology, Hospital Universitari Son Espases, Palma, Spain.

Elisabet Pol-Pol (E)

Balearic Islands Health Research Institute (IdISBa), Palma, Spain; Department of Immunology, Hospital Universitari Son Espases, Palma, Spain.

Adrian Ferré-Beltrán (A)

Department of Internal Medicine, Hospital Universitari Son Espases, Palma, Spain.

Francisca Artigues-Serra (F)

Department of Internal Medicine, Hospital Universitari Son Espases, Palma, Spain.

M Luisa Martin-Pena (ML)

Department of Internal Medicine, Hospital Universitari Son Espases, Palma, Spain; Balearic Islands Health Research Institute (IdISBa), Palma, Spain.

Jaime Pons (J)

Balearic Islands Health Research Institute (IdISBa), Palma, Spain; Centro de Investigación Biomedica en Red (CIBER) de Enfermedades Respiratorias, Hospital Universitari Son Espases, Palma, Spain; Department of Immunology, Hospital Universitari Son Espases, Palma, Spain.

Javier Murillas (J)

Department of Internal Medicine, Hospital Universitari Son Espases, Palma, Spain; Balearic Islands Health Research Institute (IdISBa), Palma, Spain; Universitat de les Illes Balears. Palma de Mallorca, Illes Balears, Spain.

Antonio Oliver (A)

Balearic Islands Health Research Institute (IdISBa), Palma, Spain; Department of Microbiology, Hospital Universitari Son Espases, Palma, Spain; Universitat de les Illes Balears. Palma de Mallorca, Illes Balears, Spain.

Melchor Riera (M)

Department of Internal Medicine, Hospital Universitari Son Espases, Palma, Spain; Balearic Islands Health Research Institute (IdISBa), Palma, Spain; Universitat de les Illes Balears. Palma de Mallorca, Illes Balears, Spain.

Joana M Ferrer (JM)

Balearic Islands Health Research Institute (IdISBa), Palma, Spain; Department of Immunology, Hospital Universitari Son Espases, Palma, Spain; Universitat de les Illes Balears. Palma de Mallorca, Illes Balears, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH